Skip to content
MARKETS / NASDAQ / CBLL
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Ceribell, Inc. CBLL

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$89.1M
▲ 36.1% YoY
$-53.4M
$-41.6M
In brief

What this company does

CeriBell, Inc. generates revenue from two recurring sources: the sale of its Wearables, intended for single patient use, and a monthly subscription fee charged to hospital customers for use of Clarity, recorders, and its portal. CeriBell, Inc. recognized revenue of $89.1 million for the year ended December 31, 2025, compared to revenue of $65.4 million for the year ended December 31, 2024, representing 36% year-over-year growth. As of December 31, 2025, CeriBell, Inc. had 327 full-time employees. CeriBell, Inc.'s corporate headquarters is located at 360 N. Pastoria Avenue, Sunnyvale, California 94085.

Written from the business description in CeriBell, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth
USD 89.1M
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 89.1 · Net income -53.4
40M80M-20M-40M202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−60 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -65.6% · Net -60.0%
-20%-40%-60%202320242025
ROE
FY2025 · ROE -30.8%
-50%-100%202320242025

Each USD of equity lost 31 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -41.6
-20M-40M202320242025

Total assetsUSD 195.8M
EquityUSD 155.3M
CashUSD 40.5M
Gross debtUSD 19.8M
Net debtUSD -20.7M
Current ratio9.73×

The company holds more cash than debt.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023
Revenue $B0.10.10.0
Operating income $B−0.1−0.0−0.0
EBITDA $B−0.1−0.0−0.0
Income tax $B0.00.00.0
Net income $B−0.1−0.0−0.0
Free cash flow $B−0.0−0.0−0.0
EPS, diluted $−1.46−3.39−5.56
Dividend / sh $···
Payout %···
ROE %−30.8−102.5·
Shares out B0.040.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 80 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2023

Share this section

Download image